Evidence map›Paper›PMID 31432280›Full record

ArticleNanoscale research letters2019

A Novel Design of an Intelligent Drug Delivery System Based on Nanoantenna Particles.

M Abbas, A Kessentini, H Loukil, P Muneer, V P Thafasal Ijyas, S E Bushara, M Abdul Wase

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale research letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

M AbbasElectrical Engineering Department, College of Engineering, King Khalid University, P.O.Box 960, Abha, Asir, 61421, Saudi Arabia. mabas@kku.edu.sa.
A KessentiniDepartment of Mechanical Engineering, College of Engineering, King Khalid University, P.O.Box 960, Abha, Asir, 61421, Saudi Arabia.
H LoukilElectrical Engineering Department, College of Engineering, King Khalid University, P.O.Box 960, Abha, Asir, 61421, Saudi Arabia.
P MuneerElectrical Engineering Department, College of Engineering, King Khalid University, P.O.Box 960, Abha, Asir, 61421, Saudi Arabia.
V P Thafasal IjyasElectrical Engineering Department, College of Engineering, King Khalid University, P.O.Box 960, Abha, Asir, 61421, Saudi Arabia.
S E BusharaElectrical Engineering Department, College of Engineering, King Khalid University, P.O.Box 960, Abha, Asir, 61421, Saudi Arabia.
M Abdul WaseElectrical Engineering Department, College of Engineering, King Khalid University, P.O.Box 960, Abha, Asir, 61421, Saudi Arabia.
King Khalid University · SAUniversity of Sfax · TN

Funding

King Khalid University (R.G.P.1/67/40)
6 · The paper itself

Abstract

Compound nanoparticle drug delivery system plays an important role in the interaction with lymph nodes. There are three primary types of lymphocytes: B cells, T cells, and natural killer cells. When the cells of the immune system turn carcinogenic, they assault body cells. The lymph fluid plays an important role in attacking healthy cells of the body; hence, this paper aimed to design a drug delivery system, which can efficiently direct nanoparticles to target the infected cells, helping in high-speed elimination of such cells. The proposed design depends on the interaction between these molecules, and the intelligent nano-controller has the ability to guide the nanoparticles by anaerobic contact. The proposed design proved that the smaller the nanoparticle size and density, the less dynamic viscosity of the liquid would be, which would reflect its resistance to flow. In addition, it was concluded that hydrogen molecules play a significant role in reducing lymphatic fluid resistance due to their low density.

Indexed as

Cancer cellsDrug deliveryFluid viscosityLymphatic fluidNanoparticles

Identifiers

PMID31432280
PMCPMC6702251
OpenAlexW2969952630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.